Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Firebrand Therapeutics Inc. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This active matter is situated within 1 distinct art unit, which suggests a concentrated technical focus for the company's current patent filings. The presence of 1 pending office action indicates that the company's immediate prosecution workload is limited to the examination process for that specific filing.
The portfolio's examination is handled by 1 distinct examiner, SHIN, DANA H. As the busiest examiner for the company, SHIN, DANA H is responsible for 1 pending application. This distribution means that the company's active portfolio is currently subject to the discretion of 1 distinct examiner at the patent office. For practitioners, this centralized structure requires a deep understanding of the specific preferences and historical tendencies of SHIN, DANA H.
Because the 1 pending office action is the active matter, its progression will define the company's short-term success in the Biotechnology & Pharmaceuticals sector. The reliance on 1 distinct art unit further emphasizes the need for a prosecution strategy tailored to the specific standards of that unit. This focused administrative environment allows for a dedicated response to the requirements of the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHIN, DANA H | 1 | 26.9% | +26.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17642789 | Inhibitor of metadherin expression | SHIN, DANA H | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17642789 | Inhibitor of metadherin expression | SHIN, DANA H | — |
| Art Unit | Apps |
|---|---|
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17642789 | Inhibitor of metadherin expression | SHIN, DANA H | 1635 | §112 | Final Rejection | — | Pending | Mar 14, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFirebrand Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Dana H Shin has the most, with 1 of Firebrand Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
